BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19077237)

  • 1. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.
    Scharer CD; Laycock N; Osunkoya AO; Logani S; McDonald JF; Benigno BB; Moreno CS
    J Transl Med; 2008 Dec; 6():79. PubMed ID: 19077237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
    Fu S; Li Y; Huang J; Liu T; Hong Z; Chen A; Bast RC; Kavanagh JJ; Gershenson DM; Sood AK; Hu W
    Cancer Biol Ther; 2012 Sep; 13(11):1034-41. PubMed ID: 22895067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
    Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
    Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
    Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
    Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
    Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
    J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
    PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
    Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
    Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer.
    Duan Z; Weinstein EJ; Ji D; Ames RY; Choy E; Mankin H; Hornicek FJ
    Mol Cancer Ther; 2008 Aug; 7(8):2377-85. PubMed ID: 18687998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells.
    Zou B; Li QQ; Zhao J; Li JM; Cuff CF; Reed E
    Anticancer Res; 2013 Mar; 33(3):929-40. PubMed ID: 23482764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
    Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
    J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.
    Lin Y; Richards FM; Krippendorff BF; Bramhall JL; Harrington JA; Bapiro TE; Robertson A; Zheleva D; Jodrell DI
    Br J Cancer; 2012 Nov; 107(10):1692-701. PubMed ID: 23037716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
    Abuharbeid S; Apel J; Zugmaier G; Knabbe C; Sander M; Gilbert S; Czubayko F; Aigner A
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Feb; 371(2):141-51. PubMed ID: 15700118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.
    Evans R; Naber C; Steffler T; Checkland T; Keats J; Maxwell C; Perry T; Chau H; Belch A; Pilarski L; Reiman T
    Leuk Lymphoma; 2008 Mar; 49(3):559-69. PubMed ID: 18297535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.